Charles Schwab Investment Management Inc. Has $1.15 Million Stock Position in Zevra Therapeutics, Inc. $ZVRA

Charles Schwab Investment Management Inc. grew its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 2.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 153,331 shares of the company’s stock after purchasing an additional 3,827 shares during the period. Charles Schwab Investment Management Inc. owned about 0.28% of Zevra Therapeutics worth $1,148,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Readystate Asset Management LP increased its position in Zevra Therapeutics by 924.6% in the 1st quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock worth $5,116,000 after purchasing an additional 616,370 shares during the last quarter. AIGH Capital Management LLC increased its position in Zevra Therapeutics by 82.4% in the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after purchasing an additional 649,495 shares during the last quarter. Mystic Asset Management Inc. increased its position in Zevra Therapeutics by 8.2% in the 1st quarter. Mystic Asset Management Inc. now owns 338,902 shares of the company’s stock worth $2,538,000 after purchasing an additional 25,555 shares during the last quarter. Bank of New York Mellon Corp increased its position in Zevra Therapeutics by 11.0% in the 1st quarter. Bank of New York Mellon Corp now owns 120,433 shares of the company’s stock worth $902,000 after purchasing an additional 11,946 shares during the last quarter. Finally, Carret Asset Management LLC acquired a new position in Zevra Therapeutics in the 1st quarter worth about $271,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Zevra Therapeutics news, Director John B. Bode bought 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 19th. The stock was purchased at an average price of $9.16 per share, for a total transaction of $45,800.00. Following the purchase, the director directly owned 45,000 shares in the company, valued at $412,200. This trade represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on ZVRA shares. HC Wainwright started coverage on Zevra Therapeutics in a research report on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 target price on the stock. Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, August 13th. Cantor Fitzgerald upped their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Thursday, July 10th. Wall Street Zen downgraded Zevra Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 20th. Finally, Zacks Research downgraded Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.71.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $9.07 on Tuesday. The business has a 50 day moving average price of $10.59 and a 200 day moving average price of $8.87. Zevra Therapeutics, Inc. has a twelve month low of $6.19 and a twelve month high of $13.16. The company has a market cap of $509.10 million, a price-to-earnings ratio of -43.19 and a beta of 1.56. The company has a quick ratio of 7.81, a current ratio of 7.85 and a debt-to-equity ratio of 0.52.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.